MP63-03 EFFICACY AND SAFETY OF a NOVEL 450 NM BLUE DIODE LASER VERSUS PLASMAKINETIC ELECTROCAUTERY FOR THE TRANSURETHRAL RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER: THE PROTOCOL AND RESULT OF a MULTICENTRE RANDOMIZED CONTROLLED TRIAL

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP63-03 EFFICACY AND SAFETY OF a NOVEL 450 NM BLUE DIODE LASER VERSUS PLASMAKINETIC ELECTROCAUTERY FOR THE TRANSURETHRAL RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER: THE PROTOCOL AND RESULT OF a MULTICENTRE RANDOMIZED CONTROLLED TRIAL Kaijie Wu, Lianhua Zhang, Shuai Jiang, Tianhai Lin, YI Luo, and Dalin He Kaijie WuKaijie Wu More articles by this author , Lianhua ZhangLianhua Zhang More articles by this author , Shuai JiangShuai Jiang More articles by this author , Tianhai LinTianhai Lin More articles by this author , YI LuoYI Luo More articles by this author , and Dalin HeDalin He More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003321.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To be the first to apply a novel 450 nm blue diode laser in transurethral resection of bladder tumour (TURBt) to treat patients with non-muscle invasive bladder cancer (NMIBC) and evaluate its efficacy and safety during the preoperative period compared to the conventional plasmakinetic electrocautery. METHODS: Randomized controlled trials (RCTs) in five medical centres were conducted from October 2018 to December 2019. Patients with NMIBC were randomized to the blue laser or plasmakinetic electrocautery group for TURBt. As the first study to evaluate this novel blue laser device, the primary outcome was the effective resection rate of bladder tumours, including effective dissection and haemostasis. The secondary outcomes were the perioperative records, including operation time, postoperative indwelling catheter time, hospital stay length, blood loss, reoperation rate, wound healing and adverse events. RESULTS: A total of 174 patients were randomized to either the blue laser group (85 patients) or plasmakinetic electrocautery group (89 patients). There was no statistical significance in the clinical features of bladder tumours, including tumour site, number and maximum lesion size. Both the blue laser and plasmakinetic electrocautery could effectively dissect all visible bladder tumours. The operation time for patients in the blue laser group was longer (p=0.001), but their blood loss was less than that of patients in the control group (p=0.003). There were no differences in the postoperative indwelling catheter time, hospital stay length, reoperation rate or other adverse events. However, the patients undergoing TURBt with the blue laser showed a faster wound healing at 3 months after operation. CONCLUSIONS: The novel blue laser could be effectively and safely used for TURBt in patients with NMIBC, and this method was not inferior to plasmakinetic electrocautery during the perioperative period. However, TURBt with the blue laser may provide the benefit to reduce preoperative blood loss and accelerate postoperative wound healing. Moreover, longer follow-up to confirm recurrence-free survival benefit was required. Source of Funding: This study was fifinancially supported by the National Key Research and Development Program (2019YFC0121501) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e871 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kaijie Wu More articles by this author Lianhua Zhang More articles by this author Shuai Jiang More articles by this author Tianhai Lin More articles by this author YI Luo More articles by this author Dalin He More articles by this author Expand All Advertisement PDF downloadLoading ...